BRIEF—Mesoblast appoints new chief medical officer

Australian stem cell therapy company Mesoblast has appointed Eric Rose, since 2013 a non-executive director, to the role of chief medical officer.

Mesoblast, which is listed on the Nasdaq as well as the Australian Securities Exchange, seeks to be a global leader in allogeneic cellular medicines for inflammatory diseases.

Chief executive Silviu Itescu said: “We are delighted to have Dr Rose move into the critical CMO position for Mesoblast at such an important period in the company’s development.”

“He is a world-renowned physician with extensive commercialization experience and a proven track record in successfully navigating products through the FDA in addition to his extensive network across government, regulatory bodies and the pharma industry.”